National Centre for Pharmacoeconomics

National Centre for

NCPE Ireland

Dupilumab (Dupixent®) HTA ID: 19056

Dupilumab is indicated for the treatment of moderate-to-severe atopic dermatitis in adolescents 12 years and older who are candidates for systemic therapy.

NCPE Assessment Process Complete
Rapid review commissioned 17/12/2019
Rapid review completed 17/01/2020
Rapid Review outcome A HTA is not recommended. The NCPE recommends that dupilumab not be considered for reimbursement at the submitted price*.


*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013